Why the study?
The prognostic importance of periprocedural myocardial infarction (pMI) and its inclusion in composite outcomes of coronary revascularization trials remain controversial.
Is periprocedural myocardial infarction a surrogate for all-cause or cardiac mortality and quality of life in coronary revascularization trials?
Is periprocedural myocardial infarction a surrogate for all-cause or cardiac mortality and quality of life in coronary revascularization trials?
Large periprocedural myocardial infarction correlates with subsequent mortality and reduced quality of life, supporting its inclusion as an outcome measure in coronary revascularization trials.
Answers are grounded in this paper and cite their sources.
Larger pMI is a clinically meaningful endpoint; supports its inclusion as surrogate for mortality and QoL in revascularization trials.
Background: The prognostic importance of periprocedural myocardial infarction (pMI) and its inclusion in the composite outcomes of coronary revascularization trials are controversial. We assessed whether pMI is a surrogate for all-cause or cardiac mortality and quality of life (QoL) outcomes in coronary revascularization trials. Methods: ). The criterion for surrogacy was set at 0.7. Subgroup analyses based on pMI definition and on key clinical/procedural variables were performed. Conclusions: In the published coronary revascularization trials, pMI defined by larger biomarker elevations was associated with subsequent mortality and reduced QoL. These findings suggest that large pMI should be included as an outcome measure in coronary revascularization trials.
No takes yet. Share an insight, caveat, or question.
Gaudino et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: